Novalis LifeSciences

Novalis LifeSciences LLC is a venture capital firm established in 2017 and based in Hampton, New Hampshire. It focuses on investing in small to medium-sized companies within the life sciences sector, specifically targeting biopharma therapeutics, molecular diagnostics, life science tools, genomics, synthetic biology, and agricultural biotechnology. The firm is led by Dr. Marijn E. Dekkers, who has a notable background as the former CEO of Bayer AG and Thermo Fisher Scientific. Novalis collaborates with a diverse group of specialists, each an expert in their respective fields, to identify and support breakthrough technologies that can advance the life sciences industry. As a Registered Investment Adviser, Novalis LifeSciences aims to foster innovation and growth in the life science landscape.

Marijn Dekkers

Chairman / Founder

16 past transactions

eTheRNA immunotherapies

Series B in 2022
eTheRNA immunotherapies NV specializes in the development of mRNA-based immunotherapies aimed at enhancing the human immune system's response to cancer and infectious diseases. The company's innovative TriMix technology specifically targets dendritic cells, which play a crucial role in initiating immune responses. By harnessing this technology, eTheRNA seeks to provide more effective and safer treatment options for patients with conditions such as melanoma and triple-negative breast cancer. Founded in 2013 and headquartered in Niel, Belgium, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its research and development efforts. The company is dedicated to advancing the field of immunotherapy to improve patient outcomes.

Animol Discovery

Series B in 2022
Animol is building its own pipeline of break-through proprietary veterinary small molecules led by a team of animal health industry experts with vast experience in bringing drugs to market. With our unique and powerful technology platform we deliver innovative medicines that are specifically designed for the needs of veterinary patients.

Enko Chem

Series C in 2022
Enko Chem, Inc. is a company focused on discovering and developing innovative small-molecule products aimed at protecting crops from pests and diseases. Established in 2017 and based in Woburn, Massachusetts, the company utilizes a proprietary technology platform to create safe and cost-effective solutions that contribute to sustainable food production. Through its research and development efforts, Enko Chem seeks to address the challenges faced by farmers while promoting environmentally responsible agricultural practices.

Vizgen

Series C in 2022
Vizgen, Inc. is a biotechnology company that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. The company's flagship technology, MERFISH, utilizes multiplexed single-molecule imaging to accurately measure the quantity and spatial distribution of RNA within individual cells. This innovative approach facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights into various applications, including oncology, immunology, neuroscience, infectious disease, and regenerative medicine. Established in 2019 and based in Cambridge, Massachusetts, Vizgen is committed to advancing research by enabling high-throughput and cost-effective analysis of complex biological systems at a cellular level.

Sherlock Biosciences

Series B in 2022
Sherlock Biosciences, Inc., a biotechnology company, develops molecular diagnostics solutions. It offers SHERLOCK, a CRISPR-based method to detect and quantify specific genetic sequences, and INSPECTR, a synthetic biology-based molecular diagnostics platform. The company offers its products in the areas of precision oncology, infection identification, food safety, at-home tests, and disease detection. The company was incorporated in 2018 and is based in Cambridge, Massachusetts.

Ori Biotech

Series B in 2022
Ori Biotech is a developer of a manufacturing platform used to help patients get access to lifesaving treatments. Ori has developed a proprietary, flexible manufacturing platform that closes, automates, and standardizes manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial-scale manufacturing. The company aims to speed up the innovation of cell and gene therapies through the manufacturing platform it is bringing to market.

SkylineDX

Venture Round in 2021
SkylineDx B.V. is a biotechnology company based in Rotterdam, the Netherlands, specializing in the development and commercialization of gene signature-based diagnostic tests aimed at personalizing treatment in oncology. The company focuses on molecular diagnostics for blood cancers, offering tools such as the AMLprofiler, which identifies subtypes of Acute Myeloid Leukemia, and the MMprofiler, a microarray-based service for diagnosing Multiple Myeloma. These diagnostics assist healthcare professionals in making informed therapy decisions tailored to individual patients. SkylineDx collaborates with academic, pharmaceutical, and industrial partners to advance the development of companion diagnostics and other related tests. The company was founded in 2005 and was previously known as Skyline Diagnostics B.V. before rebranding in 2013.

AgBiome

Series D in 2021
AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing innovative biological products for the agriculture industry. Founded in 2012, AgBiome utilizes advanced genomics and screening technologies to identify plant-associated microbes that enhance plant health, pest resistance, and crop yields. The company manufactures fungicides to protect crops from soil-borne and foliar diseases while also employing a platform that captures and screens diverse microbes for their effectiveness against insects, diseases, and nematodes. AgBiome collaborates with leading agricultural firms to accelerate its discovery process and deliver solutions that address critical challenges in global food production. With a workforce of approximately 87 employees and a state-of-the-art laboratory and greenhouse facility in the Research Triangle Park, AgBiome aims to provide sustainable and effective solutions for farmers facing significant agricultural issues.

AgBiome

Series D in 2021
AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing innovative biological products for the agriculture industry. Founded in 2012, AgBiome utilizes advanced genomics and screening technologies to identify plant-associated microbes that enhance plant health, pest resistance, and crop yields. The company manufactures fungicides to protect crops from soil-borne and foliar diseases while also employing a platform that captures and screens diverse microbes for their effectiveness against insects, diseases, and nematodes. AgBiome collaborates with leading agricultural firms to accelerate its discovery process and deliver solutions that address critical challenges in global food production. With a workforce of approximately 87 employees and a state-of-the-art laboratory and greenhouse facility in the Research Triangle Park, AgBiome aims to provide sustainable and effective solutions for farmers facing significant agricultural issues.

Modality.AI

Seed Round in 2021
Modality.AI, Inc. specializes in AI-driven healthcare screening solutions that focus on monitoring and assessing patients' health through conversational interactions. The company's platform utilizes audio-visual biomarkers and engages patients via dialogue and video to provide continuous health assessments. This technology is particularly beneficial for pharmaceutical companies, as it enhances the efficiency of clinical trials for therapies targeting neurological and mental health conditions. By analyzing multimodal data, Modality.AI delivers objective measures that correlate with clinical outcomes, facilitating self-driven neurological assessments. Founded in 2018 and headquartered in San Francisco, California, Modality.AI aims to improve health evaluations and streamline the clinical trial process.

Vizgen

Series B in 2021
Vizgen, Inc. is a biotechnology company that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. The company's flagship technology, MERFISH, utilizes multiplexed single-molecule imaging to accurately measure the quantity and spatial distribution of RNA within individual cells. This innovative approach facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights into various applications, including oncology, immunology, neuroscience, infectious disease, and regenerative medicine. Established in 2019 and based in Cambridge, Massachusetts, Vizgen is committed to advancing research by enabling high-throughput and cost-effective analysis of complex biological systems at a cellular level.
Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.

Enko Chem

Series B in 2020
Enko Chem, Inc. is a company focused on discovering and developing innovative small-molecule products aimed at protecting crops from pests and diseases. Established in 2017 and based in Woburn, Massachusetts, the company utilizes a proprietary technology platform to create safe and cost-effective solutions that contribute to sustainable food production. Through its research and development efforts, Enko Chem seeks to address the challenges faced by farmers while promoting environmentally responsible agricultural practices.

eTheRNA immunotherapies

Series B in 2020
eTheRNA immunotherapies NV specializes in the development of mRNA-based immunotherapies aimed at enhancing the human immune system's response to cancer and infectious diseases. The company's innovative TriMix technology specifically targets dendritic cells, which play a crucial role in initiating immune responses. By harnessing this technology, eTheRNA seeks to provide more effective and safer treatment options for patients with conditions such as melanoma and triple-negative breast cancer. Founded in 2013 and headquartered in Niel, Belgium, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its research and development efforts. The company is dedicated to advancing the field of immunotherapy to improve patient outcomes.

Biotalys

Series C in 2020
Biotalys is a green biotech company that employs its proprietary Agrobody technology platform to develop crop protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. It was incorporated in 2012 and is based in Ghent, Belgium.

Allurion

Venture Round in 2020
Allurion Technologies, Inc. is a medical device company based in Natick, Massachusetts, founded in 2009. It specializes in developing innovative solutions for weight loss, particularly through its flagship product, the Allurion Balloon. This unique intragastric balloon is designed to be swallowed in capsule form, allowing for a non-surgical approach to obesity treatment. Once ingested, the balloon expands in the stomach, promoting a feeling of fullness to aid in weight loss. The company also offers the Allurion Program, which includes AI-powered remote monitoring, a behavior change program, and telehealth services to support patients throughout their weight loss journey. Allurion's approach aims to provide effective weight management without the need for surgery or endoscopy.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.